FDA Clears Signos as First Over-the-Counter Continuous Glucose Monitor for Weight Management

The U.S. Food and Drug Administration (FDA) has officially granted clearance to the Signos Glucose Monitoring System, marking a significant milestone as the first-ever over-the-counter continuous glucose monitoring (CGM) system indicated specifically for weight management. This clearance positions Signos to address the growing public health challenges of obesity and metabolic dysfunction by empowering users with real-time, personalized health data.

The Signos system is an innovative combination of a wearable biosensor and an AI-driven smartphone app. It integrates the Stelo by Dexcom glucose biosensor to continuously measure glucose levels in the interstitial fluid. This data is then translated by Signos’s artificial intelligence platform into actionable insights, helping users understand how their unique biology responds to various lifestyle factors, including food choices, exercise, sleep patterns, and stress.

Shifting the Paradigm of Weight Management

Historically, CGMs have been a crucial tool for individuals with Type 1 and Type 2 diabetes, providing them with the data necessary to manage blood sugar levels and insulin dosages. The FDA’s clearance of Signos for weight management expands the application of this technology to a broader population, particularly the 73.6% of U.S. adults who are overweight or obese and the 88% who are considered metabolically unhealthy.

The company’s CEO, Sharam Fouladgar-Mercer, emphasized that the goal is to give individuals “ownership over their health and weight journeys.” The approach moves away from traditional restrictive dieting and instead focuses on providing users with information that helps them make informed, sustainable decisions based on their body’s real-time responses.

According to research cited by Signos, this data-driven approach is highly effective in promoting behavioral change. The company reports that approximately 87% of users change their food choices after seeing glucose feedback, and nearly half are motivated to exercise when they observe a glucose spike. More than 90% of users have reported that the CGM helps them adopt a healthier lifestyle.

Product Availability and Future Implications

The Signos CGM is available through a quarterly subscription plan that includes six CGMs. While the company notes that coverage may be available through health savings accounts (HSAs) or flexible spending accounts (FSAs), it advises patients to check with their healthcare providers.

The clearance of the Signos system represents a new frontier in public health technology. By making CGM technology accessible for weight management without a prescription, it offers a powerful tool to a wider audience, potentially helping to mitigate the rising rates of chronic diseases associated with poor metabolic health.